Navigation Links
PCI Ventures Company Liquid Biotech USA, Inc. Announces Raising $2M in Seed Capital to Develop its Proprietary Platform Technology for Cancer Diagnostics and Gene Discovery

PHILADELPHIA, Dec. 2, 2015 /PRNewswire/ -- Liquid Biotech USA, Inc. (LB) today announced that it had raised $2M in seed capital from a corporate investor, Oncolys Biopharma, Inc. (TYO:4588).  LB, a spin out from the Penn Center for Innovation, the University of Pennsylvania's commercialization organization, will use the capital to further develop and refine its proprietary technology. The LB technology can identify, then isolate, individual circulating tumor cells (CTCs)—cells frequently found in the blood of cancer patients—from liquid biopsies.  The identification and analysis of CTCs can lead to better prognostic and diagnostic tests, and offers a new approach to uncover novel cancer pathways, thus permitting development of next-generation cancer therapeutics.

"The high mortality rate seen in advanced cancer is due to the highly disseminated, metastatic nature of the disease," said Dr. Philip M. Sass, Chairman, President, and CEO of Liquid Biotech USA, Inc. "Our technology can provide a non-invasive, more sensitive, and rapid diagnostic test to potentially detect metastatic cancer earlier. Moreover, because we can isolate individual tumor cells from cancer patients in real time, we can use the isolated CTCs derived directly from cancer patients to develop innovative biomarkers, discover novel cancer pathways, and potentially allow the oncologist to change the patient's therapy in real time to match the cancer cells' genetics as cancer cells mutate during the course of treatment."

"We are excited to have the support of our corporate sponsor, Oncolys Biopharma, Inc. (OBP) for both their technology and their confidence to support us financially to further develop the technology," stated Jeffrey M. Janco, Executive Vice President, Chief Operating Officer and member of the Board of Liquid Biotech USA, Inc.  "The funding we have obtained gives us a good runway to develop proof-of-concept that our diagnostic test has the sensitivity to detect cancer in a clinical setting."

About Liquid Biotech USA:

Liquid Biotech USA, Inc.'s mission is to employ our novel, proprietary technology to measure circulating tumor cells (CTCs) in cancer patients in order to develop sensitive, non-invasive diagnostic testing.  LB supports internal, corporate, and academic research by analyzing isolated individual CTCs by employing whole genomic DNA sequencing technology, uncovering novel biomarkers as well as new cancer pathways to support drug development.

About PCI, PCI Ventures and UPstart:

The Penn Center for Innovation's (PCI) mission is to empower ideas into becoming real world solutions that benefit society. As a one-stop-shop for all innovation and commercialization needs, PCI facilitates industry-sponsored research, corporate alliances, straight licensing, and new venture creation. Within PCI, the PCI Ventures team provides new company formation services for Penn's leading research and innovations. PCI Ventures actively seeks entrepreneurs and investors to lead companies and to provide funding for new ventures. PCI Ventures also provides a suite of products and services to incubate the development of early stage technology-based businesses.

UPstart, one of the services at PCI Ventures, is a virtual incubator that helps scientists and innovators to form and launch new companies based on selected inventions and innovative technologies. Since 2010, UPstart has worked with more than 100 faculty and staff members, bringing their discoveries to the commercial market. UPstart currently supports more than 50 companies, collectively obtaining $7.5 million in funding. The UPstart portfolio includes companies in life sciences, medical devices, healthcare management, advanced materials, information technology, and robotics.

Company Contact:
Dr. Philip M. Sass
Chairman, President and CEO
Liquid Biotech USA, Inc.

SOURCE Liquid Biotech USA, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
2. Turnstone Biologics Completes Series A Financing Led by Versant Ventures, Strengthens Management Team
3. Macmillan Higher Education and Macmillan New Ventures to become singular higher education unit: Macmillan Learning
4. Aspire Ventures and Yellow Brick Capital Advisers (UK) Limited Announce Merger & Formation of Aspire Universal
5. Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation
6. Clarus Ventures Promotes Michele Park, Ph.D., to Partner
7. Deep Knowledge Ventures Flagship Investment Insilico Medicine Finalist at GPU Tech Conference
8. Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success
9. Science Center Receives $1 Million Grant from U.S. Economic Development Administration for New Phase 1 Ventures Program
10. Innovation Center @3401 Opens for Business; DreamIt Ventures and First Residents
11. A Unique Collaboration of Life Science Leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, has formed Triphase Accelerator Corporation to be an Oncology Development Accele
Post Your Comments:
(Date:12/23/2019)... (PRWEB) , ... December 23, 2019 , ... ... leak detection systems for the Pharmaceutical, Biotechnology and Medical Device Industries, is excited ... at the Parenteral Drug Association (PDA) Container Closure Integrity Testing Basic Training ...
(Date:12/14/2019)... HARBOR TOWNSHIP, N.J. (PRWEB) , ... December 12, ... ... world’s premier manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, ... major product launch of 2019. The new LDA LT80 (LOW TEMPERATURE -80C) helium ...
(Date:12/4/2019)... ... December 03, 2019 , ... Bold Brahim aka Jesse, a Spanish ... front leg. After several weeks of medical management, his condition worsened so his owner, ... Equine Orthopedics . Results revealed Jesse had a severe injury to his deep digital ...
(Date:12/2/2019)... MILWAUKEE (PRWEB) , ... December 02, 2019 , ... Registration ... (ASGCT) 23rd Annual Meeting, which will be held at the Hynes Convention Center May ... gene and cell therapy and brings together scientists, physicians, patient advocates, and other stakeholders ...
Breaking Biology Technology:
(Date:12/4/2019)... ... December 04, 2019 , ... ... Dr. Marque Todd , a regulatory toxicology expert with more than 20 years ... Expert Consultant. , Dr. Todd has extensive experience with a variety of ...
(Date:11/27/2019)... , ... November 26, 2019 , ... Personalized Stem ... put on by the Arthritis Foundation and hosted by Dr. Steven Sampson and Dr. ... which took place on October 23, 2019, highlighted the ongoing efforts to promote research, ...
(Date:11/19/2019)... (PRWEB) , ... November 19, 2019 , ... ... research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a ... partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring Bio-Rad’s Droplet ...
Breaking Biology News(10 mins):